Indications and Efficacy of JAK Inhibitors for AD : vimarsan

Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.

Related Keywords

Christopher Bunick , Lisa Swanson , Alexandra Golant , Olympics , Peter Lio , Jak Inhibitors , Atopic Dermatitis , Ruxolitinib , Upadacitinib , Abrocitinib , Efficacy , Clinical Trial , Network Metanalysis ,